Metabolic implications of opiate use during pregnancy: a literature review
DOI:
https://doi.org/10.18597/rcog.317Keywords:
pregnancy, opiate, drugs of abuseAbstract
Introduction: pregnant females consuming drugs of abuse is becoming a serious problem for pregnant women and for their babies as this habit increases the risk of complications during pregnancy and may permanently harm the infant (directly or indirectly). The present review was aimed at analysing opiate use during pregnancy, its mechanism of action, the metabolic implications and the possible consequences to this addictive behaviour for the mother and baby. It also analysed the effects of the opiate addiction treatment on pregnant women.
Methodology: information from the last 40 years included in the PubMed database as well as historicalarticles, texts and references cited in work published to date were analysed.
Results: important information related to the objectives proposed in the present review was found and analysed. It was then divided into four sections as follows: opiate use during pregnancy, mechanisms of action, consequences of using opiates during pregnancy and the effects on the newborn.
Conclusions: opiates consumed during pregnancy represent a risk factor for both the mother and baby and are related to possible complications during pregnancy and the presentation of neonatal abstinence syndrome and sudden infant death. Treatment using methadone and/or buprenorphine reduces such risk but rigorous control must be imposed to avoid possible problems related to their use.
Author Biography
José Henry Osorio
References
Craig M. Substance misuse in pregnancy. Curr Obstet Gynaecol 2001;2:365-71.
Chen CY, Lin KM. Health consequences of illegal drug use. Curr Opin Psychiatry 2009;22:287-92.
Martínez FC. Las drogas. Educación y prevención. Madrid: Cultural S.A.; 2004.
Quiroga PN, Panzuto R, Álvarez G, Mirson DJE, Ochoa CF, Assem EM, et al. First analytical chemistry study on drug abuse in the Buenos Aires (Argentina) university students. Il Farmaco 1998;53:389-94.
Oficina de las Naciones Unidas contra la Droga y el Delito (ONUDD), Organización de los Estados Americanos (OEA/CICAD). Primer Estudio Comparativo sobre Uso de Drogas en Población Escolar Secundaria de Argentina, Bolivia, Brasil, Colombia, Chile, Ecuador, Paraguay, Perú y Uruguay. Lima: Tetis Graf; 2006.
Observatorio Europeo de las Drogas y las Toxicomanías (OEDT). Informe Anual 2004. El problema de la drogodependencia en la Unión Europea y en Noruega. Bélgica: Oficina de Publicaciones Oficiales de las Comunidades Europeas; 2004.
Instituto Nacional sobre la Drogadicción de Estados Unidos (NIDA). Tendencias Nacionales. InfoFacts Departamento de Salud y Servicios Humanos de los Estados Unidos -Institutos Nacionales de la Salud. Diciembre 2004.
Observatorio Europeo de las Drogas y las Toxicomanías (OEDT). Informe Anual 2005. El problema de la drogodependencia en Europa. Bélgica: Oficina de Publicaciones Oficiales de las Comunidades Europeas; 2005.
De Lima L, Sweeney C, Palmer L, Bruera E. Potent analgesics are more expensive for patients in developing countries: a comparative study. Poster presentation at the International Association for the Study of Pain (IASP) 10th World Congress on Pain, San Diego. August 2002.
Pain & Policy Studies Group. University of Wisconsing. WHO Collaborating Center. Descripción de la disponibilidad de opioides en América Latina. Rev Iberoam Dolor 2008;3:18-22.
D’Apolito K. Substance abuse: infant and childhood outcomes. J Pediatr Nurs 1998;13:307-16.
Minozzi S, Amato L, Vecchi S, Davoli M. Tratamientos de mantenimiento con agonistas para embarazadas dependientes de opiáceos (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, número 3, 2008. Oxford: Update Software Ltd.
Kinsey BM, Jackson DC, Orson FM.Anti-drug vaccines to treat substance abuse. Immunol Cell Biol 2009;87:309-14.
Cui CL, Wu LZ, Luo F. Acupuncture for the treatment of drug addiction. Neurochem Res 2008;33:2013-22.
Orman JS, Keating GM. Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence. Drugs 2009;69:577-607.
Nessa A, Latif SA, Siddiqui NI, Hussain MA, Hossain MA. Drug abuse and addiction. Mymensingh Med J 2008;17:227-35.
Sargeant TJ, Miller JH, Day DJ. Opioidergic regulation of astroglial/neuronal proliferation: where are we now? J Neurochem 2008;107:883-97.
Nestler, EJ, Hope BT, Widnell KL. Drug addiction: a model for the molecular basis of neural plasticity. Neuron 1993;11:995-1006.
Nestler EJ, Aghajanian GK. Molecular and cellular basis of addiction. Science 1997;278:58-63.
Nestler EJ. Molecular mechanisms of drug addiction. J Neurosci 1992;12:2439-50.
Clouet DH, Iwatsubo K. Mechanisms of tolerance to and dependence on narcotic analgesic drugs. Annu Rev Pharmacol 1975;15:49-71.
Hulse GK, Milne E, English DR, Holman CD. Assessingtherelationshipbetweenmaternalopiateuse and neonatal mortality. Addiction 1998;93:1033-42.
Schneider C, Fischer G, Diamant K, Hauk R, Pezawas L, Lenzinger E. Pregnancy and drug abuse. Wien Klin Wochenschrift 1996;108:611-4.
Hulse GK, Milne E, English DR, Holman CD. The relationship between maternal use of heroin and methadone and infant birth weight. Addiction 1997;92:1571-9.
Weber JC, Kopferschmitt J. Substitution therapy of drug addicts. Presse Med 1998;27:2088-99.
Kandall SR, Doberczak TM, Jantunen M, Stein J. The methadone-maintained pregnancy. Clin Perinatol 1999;26:173-83.
Sullivan HR, Due SL. Urinary metabolites of dlmethadone in maintenance subjects. J Med Chem 1973;16:909-13.
Moody DE, Alburges ME, Parker RJ, Collins JM, Strong JM. The involvement of cytochrome P450 3A4 in the demethylation of L-alpha-acetylmethadol (LAAM), norLAAM, and methadone. Drug Metab Dispos 1997;25:1347-53.
Foster DJ, Somogyi AA, Bochner F. Methadone Ndemethylation in human liver microsomes: lack of stereo selectivity and involvement of CYP3A4. Br J Clin Pharmacol 1999;47:403-12.
Iribarne C, Berthou F, Baird S, Dréano Y, Picart D, Bail JP, et al. Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol 1996;9:365-73.
Oda Y, Kharasch ED.Metabolism of levo-alpha-Acetylmethadol (LAAM) by human liver cytochrome P450: involvement of CYP3A4 characterized by atypical kinetics with two binding sites. J Pharmacol Exp Ther 2001;297:410-22.
Juchau MR. Drug biotransformation in the placenta. Pharmacol Ther 1980;8:501-24.
Pasanen M, Pelkonen O. The expression and environmental regulation of P450 enzymes in human placenta. Crit Rev Toxicol 1994;24:211-29.
HakkolaJ, Raunio H, Purkunen R, Pelkonen O, Saarikoski S, Cresteil T, et al. Detection of cytochrome P450 gene expression in human placenta in first trimester of pregnancy. Biochem Pharmacol 1996;52:379-83.
Hakkola J, Pasanen M, Hukkanen J, Pelkonen O, Mäenpää J, Edwards RJ, et al. Expression of xenobiotic-metabolizing cytochrome P450 forms in human full-term placenta. Biochem Pharmacol 1996;51:403-11.
Jarvis MAE, Wu-Pong S, Kniseley JS, Schnoll SH. Alterations in methadone metabolism during late pregnancy. J Addict Dis 1999;18:51-61.
37.37. Pond SM, Kreek MJ, Tong TG, Raghunath J, Benowitz NL. Altered methadone pharmacokinetics in methadone-maintained pregnant women.J Pharmacol Exp Ther 1985;233:1-6.
Kreek MJ. Drug interactions in humans related to drug abuse and its treatment. Mod Methods Pharmacol 1990;6:265-82.
O’Connor PG, Fiellin DA. Pharmacologic treatment of heroin-dependent patients. Ann Intern Med 2000;133:40-54.
Toma Y, Higashiyama T, Yarborough C, Osawa Y. Diverse functions of aromatase: O-deethylation of 7ethoxycoumarin. Endocrinology 1996;137:3791-6.
Sawada M, Kitamura T, Norose T, Kitada M, Itahasbi K, Kamataki T. Metabolic activation of aflatoxin B1 by human placental microsomes. J Toxicol Sci 1993;18:129-32.
Deshmukh SV,Nanovskaya TN, Ahmed MS. Aromatase is the major enzyme metabolizing buprenorphine in human placenta. J Pharmacol Exp Ther 2003;306:1099-105.
Deshmukh SV, Nanovskaya TN, Hankins GD, Ahmed MS. N-demethylation of levo-a-acethylmethadol by human placental aromatase. J Biochem Pharmacol 2004;67:885-92.
Marquet P, Chevrel J, Lavignasse P, Lavignasse P, Merle L, Lachâtre G. Buprenorphine withdrawal syndrome in a newborn. Clin Pharmacol Therap 1997;62:569-71.
Simmat-Durand L, Lejeune C, Gourarier L; Groupe d' Etudes Grossesse et Addictions (GEGA). Pregnancy under high-dose buprenorphine. Eur J Obstet Gnecol Reprod Biol 2009;142:119-23.
Fischer G, Johnson RE, Eder H, Jagsch R, Peternell A, Weninger M, et al. Treatment of opiod-dependent pregnant women with buprenorphine. Addiction 2000;95:239-44.
Lim S, Prasad MR, Samuels P, Gardner DK, Cordero L. High-dose methadone in pregnant women and its effect on duration of neonatal abstinence syndrome. Am J Obstet Gynecol 2009;200:70.e1-5.
García del Río M, Lastra-Sánchez G, Medina-Soto A, Martínez-León M, Lucena-Travé J, Martínez-Valverde A. Enfoque diagnóstico-terapéutico del hijo de madre drogadicta. En: Behrman R, Kliegman RM, Arvin AM, editores. Nelson Tratado de Pediatría. 15a. ed. 1999. p.119-25.
Echeverría-Lecuona J.Drogas en el embarazo y morbilidad neonatal. An Pediatr 2003;58:519-22.
Finnegan LP, Ehrlich S. Maternal drug abuse during pregnancy: evaluation and pharmacotherapy for neonatal abstinence. Mod Methods Pharmacol 1990;6:255-63.
Johnson RE, Jones HE, Jasinski DR, Svikis DS, Haug NA, Jansson L, et al. Buprenorphine treatment of pregnant opioid-dependent women: maternal and neonatal outcomes. Drug Alcohol Depend 2001;63:97-103.
Connaughton JF, Finnegan LP, Schut J, Emich,JP. Current concepts in the management of the pregnant addict. Addict Dis 1975;2:21-35.
Blinick G, Wallach RC, Jerez E. Pregnancy in narcotics addicts-treated by medical withdrawal: the methadone detoxification program. Am J Obstet Gynecol 1969;105:997-103.
Barr GA, Jones K. Opiate withdrawal in the infant. Neurotoxicol Teratol 1994;16:219-25.
Blinick G, Wallach RC, Jerez E, Ackerman BD. Drug addict ion in pregnancy and the neonate. Am J Obstet Gynecol 1976;125:135-42.
Dashe JS, Sheffield JS, Olscher DA, Todd SJ, Jackson GL, Wendel GD. Relationship between maternal methadone dosage and neonatal withdrawal. Obstet Gynecol 2002;100:1244-9.
Kaltenbach KA, Finnegan LP. Studies of prenatal drug exposure and environmental research issues: the benefits of integrating research within a treatment program. NIDA Res Monogr 1992;117:259-70.
Suresh S, Anand K. Opioid tolerance in neonates: a state-of-the-art review. Paediatr Anaesth 2001;11:511-21.
Finnegan LP. Perinatal substance abuse: comments and perspectives. Semin Perinatol 1991;15:331-9.
Kandall SR, Gaines J, Habel L, Davidson G, Jessop D. Relationship of maternal substance abuse to subsequent sudden infant death syndrome in offspring. J Pediatr 1993;123:120-6.
Ward SL, Schuetz S, Kirshna V, Bean X, Wingert W, Wachsman L, et al. Abnormal sleeping ventilatory pattern in infants of substance-abusing mothers. Am J Dis Child 1986;140:1015-20.
Marsh DF, Hatch DJ, Fitzgerald M. Opioid systems and the newborn. Br J Anaesth 1997;79:787-95.
How to Cite
Downloads
Downloads
Published
Issue
Section
License
Copyright (c) 2016 Revista Colombiana de Obstetricia y Ginecología
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
